Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug

Boehringer Ingelheim has inked an outcomes-based contract with pharmacy benefit manager Prime Therapeutics for its oral Type II diabetes drug, Jardiance.
The medication is designed to cut the risk of cardiovascular death in adult patients with Type II diabetes and established heart disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug appeared first on MassDevice.

Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Pharmaceuticals Boehringer Ingelheim Pharmaceuticals Source Type: news